Tau proteins in the cerebrospinal fluid of patients with subacute sclerosing panencephalitis

Brain and Development

Volumn 32, Issue 6, 2010, Pages 467-471

  Yuksel, Deniz ^a,d   Yilmaz, Deniz ^a   Uyar, Neval Y ^b   Senbil, Nesrin ^a   Gurer, Yavuz ^a   Anlar, Banu ^c  

^a DR SAMI ULUS CHILDREN S HOSPITAL   (Turkey)

^b Duzen Laboratories   (Turkey)

^c HACETTEPE UNIVERSITY   (Turkey)

^d Dr Faruk Sukan Children's Hospital   (Turkey)

Author keywords

Neurodegeneration; Subacute sclerosing panencephalitis; Tau

Indexed keywords

GLUCOSE; IMMUNOGLOBULIN G; MEASLES VACCINE; PROTEIN S100B; TAU PROTEIN;

ADOLESCENT; AGE; ANTIBODY TITER; ARTICLE; AUTOPSY; CHILD; CONTROLLED STUDY; DISEASE COURSE; EEG ABNORMALITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LATENT PERIOD; MAJOR CLINICAL STUDY; MALE; MEASLES; MENTAL HEALTH; MYOCLONUS; NEUROFIBRILLARY TANGLE; NEUROLOGIC DISEASE; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PROTEIN ANALYSIS; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN PHOSPHORYLATION; SEX DIFFERENCE; SUBACUTE SCLEROSING PANENCEPHALITIS;

BRAIN; CHILD; FEMALE; HUMANS; MALE; NERVE GROWTH FACTORS; PHOSPHORYLATION; S100 PROTEINS; SUBACUTE SCLEROSING PANENCEPHALITIS; TAU PROTEINS;

EID: 77952542564     PISSN: 03877604     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.braindev.2009.11.009     Document Type: Article

References (24)

1. Anlar B. Subacute sclerosing panencephalitis: diagnosis and drug treatment options. CNS Drugs 1997, 7:111-120.
2. Wisniewski H.M., Dymecki J., Wegiel J., Kulczycki J., Sidor B., Grundke-Iqbal I., et al. Neurofibrillary pathology in subacute sclerosing panencephalitis. Dementia 1991, 2:133-141.
3. Robert M., Mathuranath P.S. Tau and taupathies. Neurol India 2007, 55:11-16.
4. Iqbal K., Alonso Adel C., Chen S., Chohan M.O., El-Akkad E., Gong C.X., et al. Tau pathology in Alzheimer disease and other tauopathies. Biochim Biophys Acta 2005, 1739:198-210.
5. Blennow K. Cerebrospinal fluid protein biomarkers for Alzheimer's disease. NeuroRx 2004, 1:213-225.
6. Buerger K., Ewers M., Pirttila T., Zinkowski R., Alafuzoff I., Teipel S.J., et al. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain 2006, 129:3035-3041.
7. Satoh K., Shirabe S., Eguchi H., Tsujino A., Eguchi K., Satoh A., et al. 14-3-3 Protein, total tau and phosphorylated tau in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease and neurodegenerative disease in Japan. Cell Mol Neurobiol 2006, 26:45-52.
8. Sjogren M., Davidsson P., Tullberg M., Minthon L., Wallin A., Wikkelso C., et al. Both total and phosphorylated tau are increased in Alzheimer's disease. J Neurol Neurosurg Psychiatry 2001, 70:624-630.
9. Hartmann A.P., Almeida S.M., Livramento J.A., Nitrini R., Takahashi D., Caramelli P., et al. Hyperphosphorylated tau protein in the cerebrospinal fluid of patients with Alzheimer's disease and other dementias: preliminary findings. Arq Neuropsiquiatr 2004, 62:751-755.
10. Liberski P.P., Papierz W., Alwasiak J. Creutzfeldt-Jacob disease with plaques and paired helical filaments. Acta Neurol Scand 1987, 76:428-432.
11. Wozniak M.A., Itzhaki R.F., Shipley S.J., Dobson C.B. Herpes simplex virus infection causes cellular β-amyloid accumulation and secretase up-regulation. Neurosci Lett 2007, 429:95-100.
12. Jabbour J.T., Duenas D.A., Modlin J. SSPE: clinical staging, course, and frequency. Arch Neurol 1975, 32:493.
13. Dyken P.R., Swift A., Durant R.H. Long term follow-up of patients with subacute sclerosing panencephalitis. Ann Neurol 1982, 11:359-363.
14. Yalaz K., Anlar B., Oktem F., Aysun S., Ustacelebi S., Gurcay O., et al. Intraventricular interferon and oral inosiplex in the treatment of subacute sclerosing panencephalitis. Neurology 1992, 42:488-491.
15. Oktem F., Nester M.J., Anlar B. Mental assessment in subacute sclerosing panencephalitis: Hacettepe cognitive short assessment scale. J Child Neurol 1997, 12:398-402.
16. Savasir I., Sezgin N., Erol N. Ankara developmental screening inventory handbook [Ankara Gelisimsel Tarama Envanteri El kitabi, AGTE] 2005, Rekmay, Ankara. 3rd ed.
17. Schulze H.A.F., David E. Besonderheiten der subakuten sklerosierenden leukoencephalitis im vergleich einiger deutscher und polnischer falle. Neuropatol Pol 1967, 5:50-67.
18. Gullotta F. Sul quadro anatomo-isto-patologico della leucoencefalite sclerosante subacuta. Acta Neurol 1963, 18:557-575.
19. McQuaid S., Allen I.V., McMahon J., Kirk J. Association of measles virus with neurofibrillary tangles in subacute sclerosing panencephalitis: a combined in situ hybridization and immunocytochemical investigation. Neuropathol Appl Neurobiol 1994, 20:103-110.
20. Anlar B., Kose G., Gurer Y., Altunbasak S., Haspolat S., Okan M. Changing epidemiological features of subacute sclerosing panencephalitis. Infection 2001, 29:192-195.
21. Yilmaz D., Aydin O.F., Senbil N., Yuksel D. Subacute sclerosing panencephalitis: is there something different in the younger children?. Brain Dev 2006, 28:649-652.
22. Petzold A., Green A.J.E., Keir G., Fairley S., Kitchen N., Smith M., et al. Role of serum S100B as an early predictor of high intracranial pressure and mortality in brain injury: Apilot study. Crit Care Med 2002, 30:2705-2710.
23. Green A., Harvey R., Thompson E., Rossor M.N. Increased S100beta in the cerebrospinal fluid of patients with frontotemporal dementia. Neurosci Lett 1997, 235:5-8.
24. Otto M., Wiltfang J., Schutz E., Zerr I., Otto A., Pfahlberg A., et al. Diagnosis of Creutzfeldt-Jakob disease by measurement of S100 protein in serum: prospective case control study. BMJ 1998, 316:577-582.